Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
← catalyst calendarNCT07265947 · readout ≤ 1,534 d
Sponsored by Tyra Biosciences, Inc (industry) · TYRA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
230estimated
Sites
17
Countries
Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-22 | actual | When the study began enrolling |
| Primary completion | Oct 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Low Grade Upper Tract Urothelial Carcinoma
Interventions
- Drug: Dabogratinib (TYRA-300) 60mg — also filed as TYRA-300
- Drug: Dabogratinib (TYRA-300) 80mg — also filed as TYRA-300
- Drug: Dabogratinib (TYRA-300) TBD — also filed as TYRA-300
Primary outcome
what the primary-completion date above is the date OFTo assess the efficacy of Dabogratinib in LG UTUC FGFR3+ participants (proportion of participants with a CR within 6 months out of all LG UTUC FGFR3+ participants)
measured within 6 months
Permalink · TYRA's whole pipeline · Catalyst calendar · Every registered study · What changed